Scavenger receptor class B, type I-mediated uptake of A1AT by pulmonary endothelial cells.

Am J Physiol Lung Cell Mol Physiol

Division of Pulmonary, Allergy, Critical Care and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana; The Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana.

Published: August 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In addition to exerting a potent anti-elastase function, α-1 antitrypsin (A1AT) maintains the structural integrity of the lung by inhibiting endothelial inflammation and apoptosis. A main serpin secreted in circulation by hepatocytes, A1AT requires uptake by the endothelium to achieve vasculoprotective effects. This active uptake mechanism, which is inhibited by cigarette smoking (CS), involves primarily clathrin- but also caveola-mediated endocytosis and may require active binding to a receptor. Because circulating A1AT binds to high-density lipoprotein (HDL), we hypothesized that scavenging receptors are candidates for endothelial uptake of the serpin. Although the low-density lipoprotein (LDL) receptor-related protein 1 (LRP1) internalizes only elastase-bound A1AT, the scavenger receptor B type I (SR-BI), which binds and internalizes HDL and is modulated by CS, may be involved in A1AT uptake. Transmission electron microscopy imaging of colloidal gold-labeled A1AT confirmed A1AT endocytosis in both clathrin-coated vesicles and caveolae in endothelial cells. SR-BI immunoprecipitation identified binding to A1AT at the plasma membrane. Pretreatment of human lung microvascular endothelial cells with SR-B ligands (HDL or LDL), knockdown of SCARB1 expression, or neutralizing SR-BI antibodies significantly reduced A1AT uptake by 30-50%. Scarb1 null mice exhibited decreased A1AT lung content following systemic A1AT administration and reduced lung anti-inflammatory effects of A1AT supplementation during short-term CS exposure. In turn, A1AT supplementation increased lung SR-BI expression and modulated circulating lipoprotein levels in wild-type animals. These studies indicate that SR-BI is an important mediator of A1AT endocytosis in pulmonary endothelium and suggest a cross talk between A1AT and lipoprotein regulation of vascular functions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538232PMC
http://dx.doi.org/10.1152/ajplung.00376.2014DOI Listing

Publication Analysis

Top Keywords

a1at
16
endothelial cells
12
scavenger receptor
8
a1at uptake
8
a1at endocytosis
8
a1at supplementation
8
uptake
6
endothelial
5
lung
5
sr-bi
5

Similar Publications

Background: Alpha-1 antitrypsin (AAT) is a medium-sized globular glycoprotein distributed in serum and tissues. In the lungs, it inhibits serine proteases and has anti-inflammatory properties in different types of cells, protecting lung tissue from damage. Mutations in the SERPINA1 gene that codes for AAT are related to asthma and chronic obstructive pulmonary disease.

View Article and Find Full Text PDF

Alpha-1 antitrypsin in COVID-19 patients: a dual-center screening study in Malaysia.

Ann Saudi Med

August 2025

From the Department of Medical Sciences II, Faculty of Medicine and Health Sciences, Universiti Sains Islam, Nilai, Negeri Sembilan, Malaysia.

Background: Alpha-1 antitrypsin (A1AT) deficiency has been recognized as an adverse prognostic determinant in severe instances of COVID-19.

Objective: To determine the A1AT phenotypes and levels in individuals at various clinical stages of COVID-19 compared to healthy controls.

Design: Case-control study.

View Article and Find Full Text PDF

COPD has been projected as the fourth leading cause of death globally by 2030. WHO recommends screening of COPD subjects for Alpha-1 Antitrypsin (A1AT) deficiency. Serum A1AT below 20% of normal value indicates A1AT deficiency.

View Article and Find Full Text PDF

SLC35A1-CDG is a very rare type of congenital disorders of glycosylation (CDG) with only five cases known to date. Here, we review the literature and present new data from a sixth patient carrying the uncharacterized variant c.133A>G; p.

View Article and Find Full Text PDF